Roche/BioNTech experimental vaccine shows early promise in pancreatic cancer

Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following surgery in a small, early trial were still alive, most without disease recurrence, more than three years later, researchers reported.